Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
April 09, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
March 05, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
February 22, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 15, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios reports fourth quarter and full year 2023 financial results and recent business highlights
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
February 02, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
January 08, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia – – Company...
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
January 03, 2024 06:30 ET
|
Agios Pharmaceuticals, Inc.
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From...
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
January 02, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
December 09, 2023 19:00 ET
|
Agios Pharmaceuticals, Inc.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition